Previous 10 | Next 10 |
home / stock / ortif / ortif news
Ortho Regenerative Technologies Reports Its Second Quarter 2022 Results Canada NewsWire Significant progress made towards securing IND approval for our Rotator Cuff repair Phase I/II trial Type A meeting with FDA scheduled on October 5, 2021 ...
Ortho Regenerative Technologies Announces Extension of FDA Clinical Hold of ORTHO-R Investigational New Drug Application PR Newswire Most complex, and majority of additional information on characterization at point of care and CMC related data submitted accepted by t...
Ortho Regenerative Technologies Announces Voting Results of its Annual General and Special Meeting of Shareholders Canada NewsWire MONTREAL , July 21, 2021 /CNW Telbec/ - Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTCQB: ORTIF) (" Ortho " or t...
Ortho Regenerative Technologies Submits Formal Response to U.S. FDA Clinical Hold Canada NewsWire All additional CMC-related data and characterization requested submitted Company is confident that additional data submitted makes for a robust and compellin...
Ortho Regenerative Technologies Announces Amendments and Extension of Unsecured Convertible Debentures and Warrants Canada NewsWire MONTREAL , July 19, 2021 /CNW/ - Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTCQB: ORTIF) (" Ortho " or the...
Ortho Regenerative Technologies (ORTIF): Q1 GAAP EPS of C$0.04.Cash position has increased from C$54,000 at the end of Q1-21 to C$1,613,000 as at the end of Q1-22.Press Release For further details see: Ortho Regenerative Technologies reports Q1 results
Ortho Regenerative Technologies Reports its First Quarter 2022 Results Canada NewsWire Submission of first Investigational New Drug ("IND") application to the US FDA for the initiation of a phase I/II clinical trial for testing ORTHO-R for rotator cuff tear repair ...
Ortho Regenerative Technologies (ORTIF) has received a clinical hold letter from the U.S. FDA related to its Investigational New Drug ((IND)) application to begin a phase I/II clinical trial for ORTHO-R, its drug/biologic combination product candidate used as an adjunct to standard of ca...
Ortho Regenerative Technologies Receives Clinical Hold Letter From the U.S. FDA Canada NewsWire Additional CMC related data and characterization requested by the FDA Company confident of providing requested information over the coming weeks Phase I/II...
Ortho Regenerative Technologies Inc. (ORTIF): FY GAAP EPS of -C$0.13.Cash balance of C$2.38MSedar filingPress Release For further details see: Ortho Regenerative Technologies Inc. reports FY results
News, Short Squeeze, Breakout and More Instantly...
Ortho Regenerative Technologies Inc Company Name:
ORTIF Stock Symbol:
OTCMKTS Market:
Ortho Regenerative Technologies Inc Website:
(NewsDirect) ChitogenX CEO Phil Deschamps joined Proactive's Natalie Stoberman with news of the company's latest federal grant and partnership deal with Polytechnique Montréal to expand the ORTHO- R platform in regenerative medicine. Deschamps said the company has obtained a $3,472,0...
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES CORPORATE NAME CHANGE TO CHITOGENX Canada NewsWire New Name to better represent Company's proprietary technology platform expanded applications beyond orthopedics MONTREAL , Sept. 7, 2022 /CNW Telbec/ ...
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN ITS U.S. PHASE I/II ROTATOR CUFF TEAR REPAIR CLINICAL TRIAL Canada NewsWire First patient surgery completed; additional surgeries already scheduled 8 clinical centres now fully initi...